Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

por Pennesi, Edoardo, Michels, Naomi, Brivio, Erica, van der Velden, Vincent H. J., Jiang, Yilin, Thano, Adriana, Ammerlaan, Anneke J. C., Boer, Judith M., Beverloo, H. Berna, Sleight, Barbara, Chen, Ying, Vormoor-Bürger, Britta, Rives, Susana, Bielorai, Bella, Rössig, Claudia, Petit, Arnaud, Rizzari, Carmelo, Engstler, Gernot, Starý, Jan, Bautista Sirvent, Francisco J., Chen-Santel, Christiane, Bruno, Benedicte, Bertrand, Yves, Rialland, Fanny, Plat, Geneviève, Reinhardt, Dirk, Vinti, Luciana, Von Stackelberg, Arend, Locatelli, Franco, Zwaan, Christian M.
Publicado 2022